| Course | NU684 Obstetrical Care |
|---|---|
| Unit | Unit 4 |
| Paper type | Seminar reflection |
| Length | About 870 words, 6 pages double-spaced |
| Format | APA 7 student paper |
| School | Purdue University Global |
| Program | MSN |
| Updated | October 2026 |
Free sample paper for NU684 Unit 4
One Tablet or Two: A Unit 4 Seminar Reflection on the Aspirin Dose for Preventing Preeclampsia
[Student Name]
Purdue University Global
NU684: Obstetrical Care
Unit 4 Seminar Reflection
[Instructor Name]
[Date]
The seminar, classmates and patient are composite; classmates are described by role; the sources cited are real.
The Question
The instructor set the scene with a composite patient: a 33-year-old in her second pregnancy, at 12 weeks, whose first pregnancy ended in preeclampsia with severe features at 31 weeks. She is clearly a candidate for low-dose aspirin. The US Preventive Services Task Force advises a nightly 81-milligram tablet from the end of the first trimester when risk is high (US Preventive Services Task Force [USPSTF], 2021), and ACOG's committee opinion recommends the same dose, ideally started before 16 weeks and continued until delivery (American College of Obstetricians and Gynecologists [ACOG], 2018). The seminar question was whether that dose is enough.
My Starting Position
I argued for 162 milligrams. My reasoning came from the trial most often cited for aspirin's benefit. The ASPRE investigators used an algorithm in early pregnancy to pick out high-risk participants, then randomized them to a 150-milligram bedtime dose or a dummy tablet, continued through week 36. Roughly 16 of every 1,000 women on aspirin developed preeclampsia that forced a preterm birth, against about 43 of every 1,000 on placebo (Rolnik et al., 2017). If the strongest evidence comes from 150 milligrams, I asked, why do U.S. guidelines recommend about half that dose?
The Pharmacist's Point
One classmate, a hospital pharmacist, raised two things. First, the 150-milligram dose reflects tablet sizes available in Europe; in the United States, the closest options are one or two 81-milligram tablets. Second, the guideline dose was set from a broader body of trials, many using doses around 60 to 100 milligrams, and there is no large randomized trial in the United States directly comparing 81 with 162 milligrams. My argument was a reasonable inference from one trial, not established evidence that 162 is better.
Our instructor then asked who the ASPRE participants were. They were selected by a screening algorithm combining history, blood pressure, uterine artery Doppler and placental markers, which most U.S. practices do not use. The trial answered whether aspirin helps a screened high-risk group, not which dose is best for a U.S. patient selected by risk factors.
I had been reading a dose comparison into a trial that compared aspirin with placebo.
The Patient the Instructor Described
It helped to return to the seminar's patient. Her history of preeclampsia with severe features at 31 weeks makes her one of the people aspirin is most likely to help, and also one of the people for whom a missed month of tablets costs the most. When the instructor asked what we would actually say to her at 12 weeks, the dose debate faded. What mattered was that she understood why she was taking aspirin, that she should start that week, take it at bedtime and keep going until delivery, and that she should know the warning signs of preeclampsia: a stubborn headache, blurred or spotty sight, upper abdominal pain on the right side and swelling of the face or hands that appears quickly. She would also need a baseline set of laboratory tests and a plan for more frequent blood pressure checks in the third trimester. Whichever dose she took, those steps would decide most of her outcome.
Where I Landed
I would now prescribe 81 milligrams, as both guidelines recommend, and explain to the patient why it matters to start before 16 weeks and take it every night. Adherence was high in ASPRE, with most participants taking at least 85 percent of their tablets, and in practice missed doses are likely to matter more than the difference between one and two tablets.
I also understand why some maternal-fetal medicine practices prescribe 162 milligrams for selected patients, such as those with previous early-onset preeclampsia like the seminar's patient, and I would not consider that wrong. If her maternal-fetal medicine consultant recommended it, I would support the plan and document the reasoning. The point I took from the seminar is that I should know which evidence supports each choice rather than repeat the larger number because it sounds more protective.
Changes I Will Make
Risk factors for preeclampsia belong in the first prenatal history, not the second-trimester visit, since starting before 16 weeks matters. I would counsel her to take aspirin at night, as in ASPRE, and to continue until delivery unless told otherwise. And I would read trials for what they compared, not for the doses they happened to use.
What Remains Unsettled
The seminar left open whether a higher dose benefits people with higher body weight, a question raised because aspirin response may vary with body size. I would look for trials designed to compare doses directly before changing my default.
Conclusion
I entered the seminar sure that two tablets were better because the best-known trial used about that dose. I left recommending one tablet, started early and taken every night, while recognizing that a specialist's choice of two is defensible in selected patients. The difference between those positions is understanding what the evidence actually tested.
References
American College of Obstetricians and Gynecologists. (2018). ACOG committee opinion no. 743: Low-dose aspirin use during pregnancy. Obstetrics & Gynecology, 132(1), e44-e52. https://doi.org/10.1097/AOG.0000000000002708
Rolnik, D. L., Wright, D., Poon, L. C., O'Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., Molina, F. S., Persico, N., Jani, J. C., Plasencia, W., Papaioannou, G., Tenenbaum-Gavish, K., Meiri, H., Gizurarson, S., Maclagan, K., & Nicolaides, K. H. (2017). Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. New England Journal of Medicine, 377(7), 613-622. https://doi.org/10.1056/NEJMoa1704559
US Preventive Services Task Force. (2021). Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force recommendation statement. JAMA, 326(12), 1186-1191. https://doi.org/10.1001/jama.2021.14781
What the NU684 Unit 4 assignment asks for
Unit 4 in NU684 usually involves a seminar debating a prevention or management question for hypertensive disorders of pregnancy, followed by a reflection. The written piece is expected to state where you began, the evidence and arguments raised, what changed and how your practice will differ. Students who cannot attend complete a written alternative with its own instructions. Instructors look for accurate description of the trials and guidelines involved, including what each trial actually compared, since dose debates often turn on that point. Applying the conclusion to a patient, ideally the seminar's own case, is usually the most heavily weighted element. One to three sources are typical: the landmark trial, the federal task force recommendation and the professional committee opinion. Two pages is the usual length, with short headings or a clear sequence from position to change to practice.
How this NU684 Unit 4 example is built
This reflection sets the scene with the instructor's patient and the two guideline recommendations, then states the writer's case for 162 milligrams built on Rolnik and colleagues' trial, expressed as rates per 1,000. A section on the pharmacist's point explains tablet sizes and the absence of a direct dose comparison, and the instructor's question about ASPRE's screening algorithm follows, under a highlighted line naming the writer's error, which a margin note marks. A section returns to the patient and lists what would matter most whatever the dose: starting that week, nightly timing, continuation and warning signs. The landing position recommends 81 milligrams while accepting a specialist's 162 for selected patients, noted in a second margin comment. Practice changes cover early risk assessment and bedtime dosing. An open question about body weight and dose ends the piece.
Reading the NU684 Unit 4 grading rubric
Reflections for the aspirin debate are marked on engagement, honesty about change, accuracy, application and writing. Engagement requires that the contributions of classmates and the instructor appear with their substance, not as a list of names. Honesty about change earns credit when the writer explains precisely what was wrong with the original reasoning. Accuracy is closely checked: the trial's dose, population and comparison, and the guideline dose and timing, should be correct. Application is weighted most, rewarding a patient-level plan that would hold whatever dose is chosen, including timing, adherence and warning signs. Recognizing when a specialist's different choice is defensible shows maturity rather than inconsistency. An open question with a plan to pursue it earns credit in many sections. Clear structure and APA references for the trial, the task force statement and the committee opinion complete the criteria.
NU684 Unit 4 help: mistakes that cost points
Reflections lose marks when they defend a starting position without engaging the evidence that challenged it, or when they switch positions without explaining why. A frequent factual error in this debate is describing ASPRE as a comparison of doses, when it compared aspirin with placebo. Another is stating the start window or dose incorrectly. Some reflections stay abstract and never return to a patient. Others treat the guideline dose as the only acceptable choice and dismiss specialists who prescribe more, which misreads the evidence. Before writing, list the trials discussed and, for each, what it compared and in whom. Then decide what you would tell the seminar's patient this week. With your notes on the trials your group argued over, a custom reflection can follow the same path.
Get an NU684 Unit 4 example written to your instructions
Share what the seminar covered, your position and the reflection prompt with its rubric. A custom reflection traces your reasoning and applies it to patients. It arrives within 24-48h; first requests are free. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
More NU684 papers and MSN samples
- NU684 Unit 1: Levels of Maternal Care Post
- NU684 Unit 2: Antibody Screen Interpretation Paper
- NU684 Unit 3: Psychosocial Care Plan
- NU684 Unit 5: Complication Case Analysis
- NU684 Unit 6: Twin Pregnancy Care Plan
- NU684 Unit 7: Management Plan
- NU684 Unit 8: Induction Plan
- NU684 Unit 9: Postpartum Infection Case Analysis
- NU684 Unit 10: Equity Improvement Proposal
- MN501 Unit 4: Professional Identity Essay
- NU682 Unit 4: Seminar Reflection
- MN502 Unit 4: Middle-range Theory Application
- NU680 Unit 4: Infertility Evaluation Brief
NU684 Unit 4 questions, answered
What if I missed the NU684 seminar?
Most sections offer a written alternative. Check its instructions, since length and elements may differ.
Should a reflection cite trials?
Yes, when it discusses a treatment's effect. Name the trial and what it compared, since dose and population matter.
How long is a seminar reflection?
Often about two pages, focused on one or two ideas and their application.
Where can I find a free NU684 Unit 4 sample paper?
The complete NU684 Unit 4 seminar reflection appears on this page. It traces a debate over 81 versus 162 milligrams of aspirin for preeclampsia prevention and explains why the writer now follows the guideline dose while accepting a specialist's higher dose in some cases.
Did the ASPRE trial compare two aspirin doses?
No. It compared 150 milligrams of aspirin with placebo in women identified as high risk by a first-trimester screening algorithm. Its result supports aspirin but does not show that a higher dose beats a lower one.